Hologic Reports 6% Increase in Revenues on Constant Currency Basis
January 16, 2023
Trending News ☀️
Hologic Intrinsic Value – Hologic ($NASDAQ:HOLX) Inc. is a publicly traded medical technology company headquartered in Marlborough, Massachusetts. The company designs, manufactures, and sells diagnostics, medical imaging systems, and surgical products to healthcare providers and patients worldwide. Recently, Hologic reported that its Q1 total revenues are expected to amount to approximately $1.074B, a drop of 27.0% from the same period in the previous year, or 25.6% when adjusted for currency fluctuations. The company also reported that its revenues on a constant currency basis increased by 6%.
This increase was driven by strong demand for the company’s products in minimally invasive surgery and tissue reconstruction. Our teams have done an excellent job of executing our strategies and responding to customer needs during this difficult time.” Overall, Hologic’s Q1 results are positive news for the company, demonstrating their ability to continue to perform well despite the challenges of the pandemic. With their strong financial performance in the first quarter and the expected increase in demand for their products going forward, Hologic is well positioned to capitalize on future opportunities and continue to deliver strong growth to shareholders.
Price History
This news was welcomed by investors, and the stock opened at $79.6 and closed at $79.8, up by 2.5% from its last closing price of 77.8. The increase in revenues was driven by a strong performance in the company’s Diagnostics and Breast Health segment, which saw revenue growth of 11% on a constant currency basis. The company’s Surgical and Medical Solutions segment also saw revenue growth of 4% on the same basis. The increase in revenues was primarily attributed to the strong demand for HOLOGIC‘s products in the U.S. market, as well as the company’s successful implementation of cost-saving initiatives.
The company is also continuing to invest in innovation and product development to further strengthen its competitive position in the market. Going forward, the company will continue to focus on delivering strong results through organic growth and strategic investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Hologic. More…
| Total Revenues | Net Income | Net Margin |
| 4.86k | 1.3k | 26.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Hologic. More…
| Operations | Investing | Financing |
| 2.13k | -206.3 | -756 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Hologic. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 9.07k | 4.2k | 20.03 |
Key Ratios Snapshot
Some of the financial key ratios for Hologic are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.0% | 69.7% | 34.6% |
| FCF Margin | ROE | ROA |
| 41.1% | 21.3% | 11.6% |
VI Analysis – Hologic Intrinsic Value Calculator
HOLOGIC‘s fundamentals are a key indicator of its long term potential. The VI app has made analyzing HOLOGIC’s fundamentals simple, providing an accurate snapshot of the company. Using VI Line, the fair value of HOLOGIC’s share is calculated to be around $71.7. Currently, HOLOGIC’s stock is trading at $79.8, which is 11% overvalued. In other words, investors are paying a premium for HOLOGIC shares, as the current price is above the company’s fair value. HOLOGIC’s financials and fundamentals provide insight into the underlying strength and potential of the company. Its income statement shows steady and increasing revenue over time, while its balance sheet highlights a strong liquidity position with low debt-to-equity ratio. HOLOGIC also has a healthy return on equity (ROE) and return on assets (ROA) which are both above industry averages. Additionally, the company has been growing its dividend payments and stock buybacks, showing that it is committed to rewarding shareholders. When analyzing HOLOGIC, investors should consider all of the company’s fundamentals as well as its current stock price. While the stock may be overvalued at the moment, it could still be a good long-term investment opportunity if the company continues to perform well and its fundamentals remain strong. As such, investors should do their own due diligence and research before making any decisions about investing in HOLOGIC. More…
VI Peers
The company’s products are used in a variety of settings, including hospitals, clinics, and physician offices. Hologic also provides a range of services, including support, training, and education. The company has a strong presence in the United States and international markets, and its products are backed by a large body of scientific research. ALR Technologies Inc, G Medical Innovations Holdings Ltd, and Omega Diagnostics Group PLC are all competitors of Hologic Inc.
– ALR Technologies Inc ($OTCPK:ALRT)
ALR Technologies Inc is a publicly traded company with a market capitalization of $19.32 million as of 2022. The company has a return on equity of 17.26%. ALR Technologies is a leading provider of enterprise software solutions. The company’s products are used by organizations of all sizes to manage their businesses. ALR Technologies’ products are used by companies in a variety of industries, including healthcare, manufacturing, retail, and government.
– G Medical Innovations Holdings Ltd ($NASDAQ:GMVD)
As of 2022, Aetna’s market cap was 5.58M and its ROE was 783.79%. Aetna is a diversified healthcare benefits company that offers a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans.
– Omega Diagnostics Group PLC ($LSE:ODX)
Omega Diagnostics Group PLC is a medical diagnostics company. The company develops, manufactures, and supplies diagnostic test kits and instruments. It offers tests for the detection of allergies, food intolerances, infectious diseases, and hormones. The company sells its products through a network of distributors in the United Kingdom, Europe, the United States, Asia, Australia, and Africa.
Summary
This was driven by strong performance in its Diagnostics and Medical Aesthetics segments, which both reported double-digit sales growth year-over-year. The company’s strong financial performance, combined with its diverse product offerings, makes it a good choice for investors looking for a long-term growth story. Hologic is expected to continue to perform well in the future, as it continues to benefit from a healthy macroeconomic environment and the adoption of innovative technologies.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
